The Broadly Neutralizing DEV_K57 Antibody, Isolated from a Convalescent Patient, in Complex with the SARS-CoV-2 RBD
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27219445 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Elina V Sinitsina und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Research Center of Virology and Biotechnology "Vector", 630559 Kol'tsovo, Russia. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Viral, Spike Glycoprotein, Coronavirus. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation, Russian Science Foundation.
Abstract (Originalsprache)
The continuous evolution of SARS-CoV-2 necessitates broadly neutralizing antibodies for robust therapeutics. In this study, we isolated 1824 single B cells from a COVID-19 convalescent donor and obtained 91 pairs of nucleotide sequences potentially encoding VH/VL domains. From this library, we generated and evaluated a panel of 38 recombinant monoclonal antibodies. Among this panel, we identified DEV_K57 as a broadly neutralizing human IgG1 antibody targeting the SARS-CoV-2 RBD. DEV_K57 exhibited in vitro neutralization breadth against diverse variants, demonstrating subnanomolar IC50 values. This in vitro efficacy was translated in vivo. In a Syrian hamster model of SARS-CoV-2 Delta infection, DEV_K57 significantly reduced viral RNA and infectious titers in both the upper and lower respiratory tracts, conferring a favorable safety profile with minimal histopathological damage. To elucidate its mechanism, we performed comprehensive biophysical and structural analyses. Biolayer interferometry revealed a high picomolar binding affinity to the RBD Delta. Furthermore, size-exclusion chromatography coupled with small-angle X-ray scattering and computational modeling uncovered a unique, stable dimeric architecture of the DEV_K57 Fab-RBD complex in solution, with a binding interface distinct from previously characterized structures. These findings underscore the value of rapid antibody isolation for pandemic preparedness against future emerging biological threats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Research Center of Virology and Biotechnology "Vector", 630559 Kol'tsovo, Russia.
- Moscow Center for Advanced Studies, 123592 Moscow, Russia.
ORCID-Profile: Andrey V Shipovalov, Irina A Osinkina, Nikita S Radchenko, Yury L Ryzhykau, Vsevolod V Sudarev, Alexander P Agafonov, Anastasia V Gladysheva
Förderung
- Ministry of Science and Higher Education of the Russian Federation
- Russian Science Foundation
Zitieren
APA
Sinitsina, E. V., Imatdinov, I. R., Tuyrin, V. Y., Shipovalov, A. V., Zaykovskaya, A. V., Osinkina, I. A., Yanshin, A. O., Radchenko, N. S., Ryzhykau, Y. L., Sudarev, V. V., Kuklina, D. D., Onkhonova, G. S., Ivleva, E. K., Agafonov, A. P., & Gladysheva, A. V. (2026). The Broadly Neutralizing DEV_K57 Antibody, Isolated from a Convalescent Patient, in Complex with the SARS-CoV-2 RBD. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27219445
Vancouver
Sinitsina EV, Imatdinov IR, Tuyrin VY, Shipovalov AV, Zaykovskaya AV, Osinkina IA, et al. The Broadly Neutralizing DEV_K57 Antibody, Isolated from a Convalescent Patient, in Complex with the SARS-CoV-2 RBD. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27219445
BibTeX
@article{Sinitsina2026,
author = {Sinitsina, Elina V and Imatdinov, Ilnaz R and Tuyrin, Vitaliy Y and Shipovalov, Andrey V and Zaykovskaya, Anna V and Osinkina, Irina A and Yanshin, Alexey O and Radchenko, Nikita S and Ryzhykau, Yury L and Sudarev, Vsevolod V and Kuklina, Daria D and Onkhonova, Galina S and Ivleva, Elena K and Agafonov, Alexander P and Gladysheva, Anastasia V},
title = {The Broadly Neutralizing DEV_K57 Antibody, Isolated from a Convalescent Patient, in Complex with the SARS-CoV-2 RBD},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27219445}
}
EUVIMED